These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 27184636

  • 1. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.
    Parikh P, Ingle M, Patel J, Bhate P, Pandey V, Sawant P.
    Saudi J Gastroenterol; 2016; 22(3):192-7. PubMed ID: 27184636
    [Abstract] [Full Text] [Related]

  • 2. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
    Ersöz G, Günşar F, Karasu Z, Akay S, Batur Y, Akarca US.
    Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
    [Abstract] [Full Text] [Related]

  • 3. COMPARATIVE ANALYSIS OF EFFICIENCY OF URSODEOXYCHOLIC ACID AND COMBINATION OF VITAMIN E AND VITAMIN C IN TREATMENT OF NON-DIABETIC NONALCOHOLIC STEATOHEPATITIS.
    Barbakadze G, Khachidze T, Sulaberidze G, Burnadze K, Jebashvili M.
    Georgian Med News; 2019 Mar; (288):81-85. PubMed ID: 31101782
    [Abstract] [Full Text] [Related]

  • 4. [Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial].
    Lee SH, Cheon GJ, Kim HS, Kim YD, Kim SG, Kim YS, Jeong SW, Jang JY, Kim BS.
    Korean J Gastroenterol; 2014 Jul; 64(1):31-9. PubMed ID: 25073669
    [Abstract] [Full Text] [Related]

  • 5. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Nadinskaia M, Maevskaya M, Ivashkin V, Kodzoeva K, Pirogova I, Chesnokov E, Nersesov A, Kaibullayeva J, Konysbekova A, Raissova A, Khamrabaeva F, Zueva E.
    World J Gastroenterol; 2021 Mar 14; 27(10):959-975. PubMed ID: 33776366
    [Abstract] [Full Text] [Related]

  • 6. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
    Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J, FRESGUN.
    J Hepatol; 2011 May 14; 54(5):1011-9. PubMed ID: 21145828
    [Abstract] [Full Text] [Related]

  • 7. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A, Swiss Association for the Study of the Liver.
    Clin Gastroenterol Hepatol; 2006 Dec 14; 4(12):1537-43. PubMed ID: 17162245
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis- A randomized pilot study.
    Kedarisetty CK, Bhardwaj A, Kumar G, Rastogi A, Bihari C, Kumar M, Sarin SK.
    Indian J Gastroenterol; 2021 Feb 14; 40(1):41-49. PubMed ID: 33772456
    [Abstract] [Full Text] [Related]

  • 9. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R, Izaola O, Gómez S, Tafur C, González G, Berroa E, Mora N, González JM, de Luis DA.
    Eur Rev Med Pharmacol Sci; 2015 Aug 14; 19(16):3118-24. PubMed ID: 26367736
    [Abstract] [Full Text] [Related]

  • 10. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
    Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M, Austrian/German NAFLD-norUDCA study group.
    Lancet Gastroenterol Hepatol; 2019 Oct 14; 4(10):781-793. PubMed ID: 31345778
    [Abstract] [Full Text] [Related]

  • 11. A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
    Fouda A, Abdelaziz AE, Hussien M, Ali AA, Abdelkawy KS, Elbarbry F.
    Eur Rev Med Pharmacol Sci; 2021 Dec 14; 25(23):7449-7459. PubMed ID: 34919247
    [Abstract] [Full Text] [Related]

  • 12. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
    Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P.
    Hepatology; 2004 Mar 14; 39(3):770-8. PubMed ID: 14999696
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function.
    Yoon S, Lee H, Ji SC, Yoon SH, Cho JY, Chung JY.
    Clin Pharmacol Drug Dev; 2021 Jan 14; 10(1):68-77. PubMed ID: 32191400
    [Abstract] [Full Text] [Related]

  • 14. Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study.
    Kim GH, Chung JW, Lee JH, Ok KS, Jang ES, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW.
    Clin Mol Hepatol; 2015 Dec 14; 21(4):379-86. PubMed ID: 26770927
    [Abstract] [Full Text] [Related]

  • 15. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.
    Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, Nonalcoholic Steatohepatitis Clinical Research Network.
    JAMA; 2011 Apr 27; 305(16):1659-68. PubMed ID: 21521847
    [Abstract] [Full Text] [Related]

  • 16. Improvement of alanine aminotransferase by administration of suplatast tosilate plus ursodeoxycholic acid in patients with resistance to ursodeoxycholic acid monotherapy on hepatitis C virus-related chronic liver disease.
    Matsuda Y, Inada M, Maeda H, Matsuyama T.
    Intern Med; 2002 Oct 27; 41(10):774-9. PubMed ID: 12412994
    [Abstract] [Full Text] [Related]

  • 17. Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease.
    Hongguang J, Xingjie H, Mingliang J, Yun L, Tongjian L, Jingmo Y, Liang L, Lifang Z.
    Pak J Pharm Sci; 2019 Jan 27; 32(1(Special)):433-437. PubMed ID: 30852481
    [Abstract] [Full Text] [Related]

  • 18. [Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome].
    Avalueva EB, Tkachenko EI, Skazyvaeva EV, Ivanov SV, Orishak EA, Lapinskiĭ IV.
    Eksp Klin Gastroenterol; 2013 Jan 27; (11):26-30. PubMed ID: 24933975
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
    Gangarapu V, Ince AT, Baysal B, Kayar Y, Kılıç U, Gök Ö, Uysal Ö, Şenturk H.
    Eur J Gastroenterol Hepatol; 2015 Jul 27; 27(7):840-5. PubMed ID: 26043290
    [Abstract] [Full Text] [Related]

  • 20. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF, Sun Y, Shen L.
    Nutrition; 2014 Sep 27; 30(9):986-91. PubMed ID: 24976430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.